Clinical Trial Results: Positive clinical trial data typically leads to increased investor confidence and a higher stock price. Conversely, negative or inconclusive results can cause the price to decline.

Regulatory Approvals: News regarding regulatory approvals or rejections from agencies like the FDA significantly impacts investor sentiment and therefore the stock price.

Partnerships and Collaborations: Announcements of partnerships with larger pharmaceutical companies or research institutions often boost the stock price, reflecting potential future revenue streams and validation of Vaxart's technology.

Market Sentiment: Overall market conditions, particularly within the biotechnology sector, can influence the price. A bullish market generally lifts stock prices, while a bearish market can depress them.

Competition: Developments from competitors in the oral vaccine space can affect Vaxart's perceived market share and future prospects, impacting its stock price.

Financial Performance: Vaxart's cash position, burn rate, and any revenue generated will influence investor confidence in the company's ability to fund its research and development efforts.

News and Media Coverage: Significant news articles, analyst ratings, and social media buzz can drive short-term price fluctuations.

Intellectual Property: Strength and scope of Vaxart's patents covering its oral vaccine technology and delivery platforms affect its long-term potential.

Management Team: The experience and reputation of Vaxart's leadership team play a role in investor confidence and the perceived ability of the company to execute its strategy.